FORTEO®

teriparatide (rDNA origin) injection

helps build new bone

Since 2002, FORTEO® has been helping physicians build bone in over 2 million patients around the world. As of today, **there is no other anabolic with the clinical and real-world experience of FORTEO®:**

- Well-established efficacy and safety profile over more than **17 years of use**[2,3]
- Used in **over 2.2 million patients** cumulatively since it was first marketed[1*]
- Backed by **patient and physician support programs** throughout the entire 24-month treatment course
- Easy-to-use delivery device **designed with patients in mind**[4]
- **Currently approved in 97 countries** for one or more indications[1]

References:

1. Eidon ®, Lilly Research Laboratories, PADR-PEN20, September 1, 2016–September 12, 2016, 1, 1, 4000187 Summary of Product Characteristics.
2. Leupold JA, et al. Calcif Tissue Int. 2016;98(3):256-271. 4. Ross A, et al. Osteoporos Int. 2011;22(2):357-362.

FORTEO Abbreviated Prescribing Information

Active ingredient: Injectable Indications: Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Hypercalcemia at baseline. Paget's disease of bone or unexplained elevations of alkaline phosphatase. Prior radiation therapy involving the skeleton. Bone malignancy or metastatic disease in the skeleton. Warnings and Precautions: Osteosarcoma. Hypercalcemia. Orthostatic hypotension. Pregnancy and lactation. Adverse Reactions: Most common adverse reactions (≥ 10%) were nausea and headache. Dosage and Administration: 20 mcg once daily administered by subcutaneous injection in the thigh or abdomen. Do not exceed 24 months of therapy. Drug Interactions: Digoxin. Thiazide diuretics. Overdosage: Hypercalcemia, hypercalciuria, hypotension, nausea and vomiting. Dosage Forms and Strengths: Pre-filled multi-dose pen delivering 250 mcg/mL solution for injection.

Full prescribing information is available upon request.
See Healthcare Professional only.

ZP THERAPEUTICS
making healthcare more accessible

ZP Therapeutics (A division of Zuellig Pharma)
Zuellig Pharma Sdn Bhd (1000186052-U(13))
No. 15, Persiaran Perak Barat, Seksyen U8, Perindustrian Bukit Jelutong,
40150 Shah Alam, Selangor Darul Ehsan, Malaysia.
T +60 3 5565 2288 | F +60 3 5565 2266
www.zuelligpharma.com